Core Insights - Daxor Corporation is participating as an exhibitor at the American College of Cardiology Annual Scientific Session, showcasing its innovative Blood Volume Analyzer [1][2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, addressing the critical issue of accurately measuring blood volume to improve patient care and reduce healthcare costs [5] - The company has developed a rapid, portable Blood Volume Analyzer (BVA) that is FDA-cleared and provides over 95% accuracy in quantifying total blood, plasma, and red cell volume [2][5] Product Benefits - The BVA system replaces subjective clinical guesswork with objective data, which is essential for optimizing fluid management and discharge timing in patients [3] - Peer-reviewed studies indicate that BVA-guided care can lead to a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality, demonstrating significant value for healthcare providers [3] Market Context - The BVA addresses the $3.5 billion annual Medicare burden associated with heart failure readmissions in the United States, highlighting its potential impact on healthcare costs [2] - Daxor's technology is positioned for scalability across both inpatient and outpatient care environments, enhancing its market reach [3]

Core Insights - Daxor Corporation experienced a transformative year in 2025, marked by significant growth in its operating division and a substantial increase in total net assets [1][6] FDA Milestone & Commercial Momentum - The company received FDA 510(k) clearance in August 2025 for its next-generation Blood Volume Analyzer, which is three times faster than previous models and developed under contract with the U.S. Department of Defense [2] - Daxor is utilizing newly raised capital to assemble these units and expand its commercial sales team in response to positive market feedback [2] Financial Performance Highlights - Total net assets reached $45,887,266 as of December 31, 2025, an increase of over $10 million from the previous year [7] - Net Asset Value per share increased to $9.07, representing a gain of $1.82 per share compared to December 31, 2024 [7] - The company recorded net realized gains on investment activity of $745,334 for the fiscal year [7] - Unaudited operating revenues increased by 45% year-over-year, driven by sales of diagnostic kits and military contracts [7] - The operating division improved its loss to $268,598 from a loss of $1,614,545 in 2024, despite heavy investments in R&D and sales team expansion [7] Operating Division Momentum - Daxor's operating division saw remarkable expansion due to increased market adoption of its Blood Volume Analysis (BVA) technology [4] - The company successfully closed a $9 million registered direct offering in January 2026, significantly strengthening its working capital for accelerated commercialization [4] - Daxor plans to transition its regulatory reporting framework to the Securities Exchange Act of 1934 to simplify financial disclosures and provide standardized GAAP metrics [5] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions [6] - The company operates a state-of-the-art manufacturing facility and is ISO certified, positioning it for accelerated market expansion [8]

Core Insights - Daxor Corporation will showcase its next-generation Blood Volume Analysis (BVA) diagnostic system at the MedAxiom Cardiovascular Transforum Fall'25 Conference, which is a key event for cardiovascular organizational performance solutions [1][2] - The launch of the new BVA system is expected to enhance sales momentum and strengthen market leadership by addressing critical issues such as hospital readmissions and resource optimization [2] - Daxor is focused on solving the healthcare challenge of accurately measuring blood volume, which is crucial for improving patient care and reducing hospital stays, particularly for conditions like heart failure [3] Company Overview - Daxor Corporation is recognized as a leader in blood volume measurement technology, with a patented, FDA-cleared BVA diagnostic system that provides real-time, precise data [3] - The company has 50 years of experience in the industry and operates a state-of-the-art manufacturing facility in the U.S., which supports its market expansion efforts [3] - Daxor's technology aims to empower clinicians to make individualized treatment decisions, thereby improving patient outcomes and enhancing efficiencies in value-based healthcare [3]

Core Insights - Daxor Corporation's BVA technology significantly reduces hospital readmissions and improves survival rates in high-cost heart failure segments, validated by new clinical data presented at the HFSA Annual Scientific Meeting [1][3] - The newly FDA-cleared BVA analyzer is expected to capture a substantial share of the multi-billion-dollar market due to its enhanced ease of use, speed, and over 95% accuracy [2][3] Clinical Validation - Clinical findings indicate that patients optimally managed with BVA technology experienced zero unplanned readmissions, contrasting sharply with 57-77% for those with imbalances in blood volume [7] - The use of BVA-guided care in LVAD implantation resulted in improved outcomes, increasing 30-day survival from 90.3% to 93.6% and 1-year survival from 79.6% to 87.8%, while reducing 30-day readmissions from 28.6% to 18.5% [7] - Patients with Cardiac Amyloidosis showed significantly higher total blood and plasma volumes, indicating the diagnostic potential of BVA for accurate treatment [7] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions like heart failure [4] - The company has 50 years of experience and operates a state-of-the-art manufacturing facility, positioning it for accelerated market expansion [4]

Core Insights - The study published in the Journal of Critical Care reveals frequent inaccuracies in clinical assessments of fluid status in critically ill patients, particularly those with sepsis and COVID-19 [1][2] - Daxor Corporation's BVA technology is highlighted as a solution to improve fluid management in critical care settings, emphasizing the need for accurate blood volume measurement [4][5] Study Findings - A significant percentage of patients were misclassified during clinical assessments, with 48% of COVID-19 patients incorrectly deemed hypervolemic when they were actually hypovolemic [8] - The study indicates that the albumin transudation rate (ATR) was persistently elevated in both sepsis and COVID-19 patients, suggesting ongoing capillary leakage [8] - Sepsis patients exhibited a higher ATR compared to COVID-19 patients, indicating more severe endothelial dysfunction despite lower admission severity scores [8] Company Positioning - Daxor's FDA-approved BVA-100™ Analyzer was utilized in the study, showcasing its capability to provide objective measurements of total blood volume and ATR [4] - The company has received FDA clearance for a new rapid BVA system, which is three times faster than the BVA-100™ and maintains over 95% accuracy, addressing urgent diagnostic needs in critical care [5][6] - Daxor is positioned for revenue expansion in critical care medicine, supported by new data, funding opportunities, and advancements in its technology [6][9]

Core Insights - Daxor Corporation is expanding its ezBVA Lab service into three regional healthcare facilities across the U.S., enhancing blood volume analysis capabilities and improving patient outcomes while reducing costs [2][3] - The ezBVA Lab provides comprehensive blood volume analysis results within 24 hours for both inpatient and outpatient settings, showcasing the efficiency and effectiveness of Daxor's technology [2][3] - Daxor's BVA technology has been integrated into various healthcare settings, including a prominent Midwest academic medical center and a leading cardiovascular institute in New Jersey, indicating its growing significance in modern healthcare [3][6] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with its BVA-100® being the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - Daxor is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]